![](/images/graphics-bg.png)
Remifentanil Protects against Lipopolysaccharide-Induced Inflammation through PARP-1NF-κB Signaling Pathway
Joint Authors
Zhang, Jian-ning
Ma, Yang
Wei, Xi-yan
Liu, Ke-yin
Wang, Hao
Han, Hui
Cui, Yi
Zhang, Ming-xiang
Qin, Wei-dong
Source
Issue
Vol. 2019, Issue 2019 (31 Dec. 2019), pp.1-8, 8 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2019-12-31
Country of Publication
Egypt
No. of Pages
8
Main Subjects
Abstract EN
Sepsis is a leading cause of death in patients with severe infection worldwide.
Remifentanil is an ultra-short-acting, potent opioid analgesic.
In the study, we aimed to investigate the role and underlying mechanism of remifentanil in lipopolysaccharide- (LPS-) induced inflammation in human aortic endothelial cells (HAECs).
HAECs were pretreated with phosphate-buffered saline (PBS) or remifentanil (2.5 μM) for 30 min, then stimulated by LPS (10 μg/ml) for another 24 h.
Poly(ADP-ribose) polymerase 1 (PARP-1) was inhibited by small interfering RNA (siRNA).
Superoxide anion production and DNA damage were analyzed by dihydroethidium (DHE) staining and comet assay.
The inducible nitric oxide synthase (iNOS), intercellular adhesion molecule 1 (ICAM-1), PARP-1, poly(ADP-ribose) (PAR), and nuclear factor-kappa B p65 (NF-κB p65) expressions were analyzed by RT-PCR or western blotting analysis.
NF-κB p65 nuclear translocation was assessed by immunofluorescence.
Compared with the control group, pretreatment with remifentanil significantly reduced superoxide anion production and DNA damage, with downregulation of iNOS, ICAM-1, and PARP-1 expressions as well as PAR expression.
Moreover, pretreatment with PARP-1 siRNA or remifentanil inhibited LPS-induced NF-κB p65 expression and nuclear translocation.
Remifentanil reduced LPS-induced inflammatory response through PARP-1/NF-κB signaling pathway.
Remifentanil might be an optimal choice of analgesia in septic patients.
American Psychological Association (APA)
Zhang, Jian-ning& Ma, Yang& Wei, Xi-yan& Liu, Ke-yin& Wang, Hao& Han, Hui…[et al.]. 2019. Remifentanil Protects against Lipopolysaccharide-Induced Inflammation through PARP-1NF-κB Signaling Pathway. Mediators of Inflammation،Vol. 2019, no. 2019, pp.1-8.
https://search.emarefa.net/detail/BIM-1192757
Modern Language Association (MLA)
Zhang, Jian-ning…[et al.]. Remifentanil Protects against Lipopolysaccharide-Induced Inflammation through PARP-1NF-κB Signaling Pathway. Mediators of Inflammation No. 2019 (2019), pp.1-8.
https://search.emarefa.net/detail/BIM-1192757
American Medical Association (AMA)
Zhang, Jian-ning& Ma, Yang& Wei, Xi-yan& Liu, Ke-yin& Wang, Hao& Han, Hui…[et al.]. Remifentanil Protects against Lipopolysaccharide-Induced Inflammation through PARP-1NF-κB Signaling Pathway. Mediators of Inflammation. 2019. Vol. 2019, no. 2019, pp.1-8.
https://search.emarefa.net/detail/BIM-1192757
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1192757